Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
REDWOOD CITY, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of...
Advanced to Cohort 6 in the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancersAbstract accepted for BDC-4182, a claudin 18.2-targeting BoltbodyTM ISAC at the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0472 | -7.29295426452 | 0.6472 | 0.65 | 0.5906 | 120612 | 0.62372908 | CS |
4 | -0.08 | -11.7647058824 | 0.68 | 0.6999 | 0.5906 | 145130 | 0.63880616 | CS |
12 | -0.13 | -17.8082191781 | 0.73 | 0.78 | 0.5906 | 165087 | 0.69877051 | CS |
26 | -0.6 | -50 | 1.2 | 1.56 | 0.5906 | 200706 | 0.84183807 | CS |
52 | -0.44 | -42.3076923077 | 1.04 | 1.56 | 0.5906 | 164380 | 0.930387 | CS |
156 | -12.6 | -95.4545454545 | 13.2 | 14.18 | 0.5906 | 203325 | 2.39584383 | CS |
260 | -21.39 | -97.2714870396 | 21.99 | 43.07 | 0.5906 | 194440 | 6.8715667 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.